Development of an in vitro diagnosis of adverse effects of FOLFOXIRI therapy for colorectal cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08799
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Yamaguchi University
• Principal Investigator: Suzuki Nobuaki 山口大学, 医学部, 特別医学研究員 (50526910)
• Co-Investigator(Kenkyū-buntansha): 恒富 亮一 山口大学, 医学部附属病院, 講師 (10420514) ; 友近 忍 山口大学, 医学部附属病院, 助教 (30403679) ; 硲 彰一 山口大学, 医学部, 特別医学研究員 (50253159) ; 渡邊 裕策 山口大学, 医学部附属病院, 助教 (80799437)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 癌

Outline of Final Research Achievements

We investigated gene polymorphisms in the whole exome to identify useful biomarkers for irinotecan toxicity other than UGT1A1. An SNP in R3H domain and coiled-coil containing 1 (R3HCC1; c.919G>A, rs2272761) showed a significant association with neutropenia (>grade 3) after FOLFIRI chemotherapy. Patients receiving irinotecan including triplet chemotherapy, FOLFOXIRI for mCRC or modified FOLFIRINOX for pancreatic cancer, also showed significant linear trends between R3HCC1 polymorphism and neutropenia. In conclusion, an SNP in the R3HCC1 gene may be a useful biomarker for the toxicity of irinotecan-containing chemotherapy for mCRC and pancreatic cancer.

Free Research Field

消化器外科

Academic Significance and Societal Importance of the Research Achievements

FOLFIRINOXを含むイリノテカン併用化学療法における副作用関連バイオマーカーとしてR3HCC1遺伝子における遺伝子多型が同定された。本バイオマーカーを事前に測定することは、より安全に化学療法を行う個別化医療へとつながることが期待される。